B.R.A.I.N. Biotechnology Research And Information Network AG: Frank Goebel, CFO of BRAIN AG, has asked the Supervisory Board for early termination of his Management Board contract for personal reasons
Frank Goebel, CFO of BRAIN AG, has asked the Supervisory Board for early termination of his Management Board contract for personal reasons
Frank Goebel will remain with the company until a suitable candidate is found The Supervisory Board will be looking for a successor immediately
BRAIN AG announces that the current CFO, Frank Goebel, intends to leave the company for private reasons before the regular expiry of his contract, which runs until October 2019. Frank Goebel informed the Chairman of the Supervisory Board of this today. He wants to allocate more time to family matters in the future and, against this background, is considering a change of residence.
The Supervisory Board regrets this decision and thanks Mr. Goebel already today for his high level of commitment and the work he has done over the past years for the BRAIN Group, acting as MD of BRAIN Capital GmbH starting in February 2015, and since November 2016 as member of the Board of BRAIN AG.
The Supervisory Board will take care of a succession plan and begin discussions with suitable candidates as soon as possible. The aim is to appoint a suitable successor by the end of the 2018 calendar year, and to then early terminate Frank Goebel's contract as CFO.
Frank Goebel will remain at the company's disposal until then, supporting a smooth transition.
B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars - BioScience and BioIndustrial. The BioScience segment comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commercialization of BRAIN's own products and active product components. Further information is available at www.brain-biotech.de/en.
07.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: B.R.A.I.N. Biotechnology Research And Information Network AG Darmstädter Straße 34-36 64673 Zwingenberg
Germany Phone: +49 (0) 62 51 / 9331-0 Fax: +49 (0) 62 51 / 9331-11 E-mail: firstname.lastname@example.org Internet: www.brain-biotech.de ISIN: DE0005203947 WKN: 520394 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service